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Introduction
Angiogenesis plays an essential role in embryogenesis, normal tissue growth, wound healing and the female reproductive cycle. It also plays a major role in various diseases. Special interest is focused on tumor growth, since tumors cannot grow more than a few millimeters in size without developing a new blood supply.
Among others, vascular endothelial growth factor (VEGF-A) is one of the key molecules for angiogenesis and for the survival of the endothelium. It is a specific endothelial cell mitogen and a strong vascular permeability factor. VEGF-A is a heparin-binding glycoprotein, secreted as a homodimer of 45 kDa by many different cell types. Several variants of VEGF-A have been described, but VEGF 165 is the most predominant protein. VEGF-A transcription is highly activated by hypoxia and by oncogenes like H-ras and several transmembrane tyrosine kinases, such as epidermal growth factor receptor and erbB2. Together, these pathways account for a significant up-regulation of VEGF-A in tumors compared to normal tissues and are of prognostic importance [1, 12] . VEGF signaling is mediated mainly by two receptors: VEGFR-1 (K d = 10-20 pM for VEGF 165 ) and VEGFR-2 (K d =75-125 pM for VEGF 165 ). The affinity for the VEGFR-1 is higher, but the cellular response is mainly dominated by VEGFR-2 [2] .
One of the research challenges in oncology is to develop new biochemical methods for tumor therapy evaluation to determine whether the chemotherapeutics is effective [3, 4] [5, 6] , biodistribution studies in animals, which are of prior importance, are not reported. Li also showed that the labeled VEGF 165 isoform showed affinity to more cell lines than the VEGF 121 and is therefore preferred in this study.
The synthesis, in vitro evaluation of and biodistribution of [
123 I]-VEGF 165 in wild-type NMRI mice as well as in tumor-bearing athymic mice are reported and discussed. If the parameters of the radiopharmacon, mainly kinetics and tumor uptake ratios, are sufficient, in vivo therapy evaluation is considered for chemotherapeutics that interfere with the VEGFR pathway, such as tyrosine kinase inhibitors or farnesyl transferase inhibitors [1] . I or Na 125 I (Bristol-Meyers Squibb, Brussels, Belgium) was added to a Iodogen-coated vial. Total reaction volume was adjusted to 140 µl, using a 0.1 M potassium phosphate buffer at pH 8.5. After 10 min at room temperature the mixture was removed from the Iodogen vial to stop the reaction. Bovine serum albumin (BSA) solution was added (Sigma, Bornem, Belgium; 250 mg BSA per 100 ml 0.1 M phosphate-buffered saline [PBS] at pH 7.2, referred to as PBS/BSA). VEGF tracer and remaining radio-iodide were separated using a standard prepacked PD-10 SEC column (Size Exclusion Chromatography, Amersham Pharmacia Biotech, Uppsala, Sweden) using PBS/BSA as eluent [7] .
Materials and methods

Synthesis of
The adsorption of the tracer to the preparative SEC column was checked using an already purified [ 123 I]-VEGF 165 solution in PBS/BSA. From this adsorption value and the initial mass of protein used, the molar fraction eluted from the column was calculated. Specific activity was calculated as the amount of radioactivity per microgram of VEGF 165 recovered at end of purification. Quality control was performed using SEC-HPLC and the radiochemical purity was calculated. Stability of the tracer was assessed in both PBS and DMEM growth medium (Bio-Whittaker, Verviers, Belgium) after various times of incubation, using PD-10 separation.
Cell cultures and binding assay
A2058 (human melanoma) cells were cultured in DMEM (Gibco, Paisley, UK), enriched with 10% of fetal bovine serum (FBS, Gibco), supplemented with 1% penicillin-streptomycin mixture (Bio-Whittaker) and 1% L-glutamine (Bio-Whittaker). Split ratios were 1:20 weekly. Both cell lines grew in an anchorage-dependent manner in tissue culture flasks and Falcon 12-well tissue culture plates (Novolab, Belgium).
Saturation binding analysis was performed on A2058 cells in 12-well cell culture plates, using three wells for each data point. After stripping of all receptor-bound proteins, using 0.1 M glycine-HCl buffer (pH 3), basic medium without FBS and increasing amounts of [ 125 I]-VEGF 165 radiotracer were added to the cells. The total incubation volume was adjusted to 1 ml. The cells were incubated for a period of 2 h at 4°C to avoid internalization. After 2 h, the supernatant was removed and the cells were washed with 1 ml of cold PBS (4°C). The supernatant and washing buffer were pooled and counted for radioactivity ("free ligand") with an automated NaI(Tl) gamma counter (CobraII Series, Canberra Packard, Meriden, CT). Two hundred microliters of trypsin-EDTA was added to the cells and incubated at 37°C for 10 min. After addition of 1800 µl of PBS, the suspension was removed and counted for radioactivity ("bound"). This experiment was repeated three times. Saturation plots were calculated using the Prism Graph Pad software (Graphpad Software), resulting in best fits for K d , B max and nonspecific binding coefficient [8] . Results were normalized for cell count, which was obtained from parallel cell culture plates, using the trypan blue method. Also, a displacement experiment with unlabeled VEGF was carried out on A2058 cells, as described by Li et al. to examine the specificity of the binding of the tracer.
In order to investigate tracer internalization, A2058 cells, grown in 12-well tissue culture plates, using three wells per data point, were incubated at 37°C for various times (ranging from 20 min to 3 h) in the presence of 0.7 nM [
125 I]-VEGF 165 . After incubation, the supernatant was removed; cells were washed with basic medium and treated with 0.1 M glycine-HCl buffer (pH 2.5) for 6 min at 4°C to remove surface-bound ligand. Cells were detached using 200 µl NaOH solution (1 M, incubation for 30 min at 37°C), re-suspended with 800 µl of water, removed and counted for radioactivity [4, 9] . This experiment was repeated three times.
Biodistribution of [
I]-VEGF 165
Both male white NMRI mice (20-25 g) and male Swiss nu/nu mice (nude, 20-25 g) were purchased from Bioservices (Schaijk, The Netherlands). All animals were treated according to the regulations of the Belgian law and animal experiments were approved by the local ethical committee. All manipulations with Swiss nu/nu mice were carried out in sterile conditions. Biodistribution on tumor-bearing mice was carried out using A2058 tumors. Cells were harvested by trypsinization or using a cell scraper in growth medium. After centrifugation for 5 min at 100 xg, cells were resuspended in serum-free growth medium. Cells were counted using the trypan blue method. Male Swiss nu/nu athymic mice were injected subcutaneously in the right flank with a suspension of approximately 5xl0 6 A2058 cells in a total volume of 200 µl serum-free growth medium. Tumor growth curves were obtained using daily sliding caliper measurement. Tumor volume was calculated as V=0.4 a 2 b, a and b being the short-axis and the long-axis of the tumor, respectively. Tumor-bearing mice were used in the biodistribution studies when tumor volume was approximately 1 ml.
NMRI and tumor-bearing nude mice were both injected intravenously through the lateral tail vein with a 100 µl solution of 2 µCi of [
123 I]-VEGF 165 (4 µCi per 100 µl for all intervals longer than 2 h). At various time points (20 s to 48 h for NMRI mice and 1 to 6 h for tumor-bearing nude mice) postinjection (p.i.), the animals were sacrificed by decapitation and blood was recovered (n =3 per time point). All organs (lung, liver, stomach, spleen, bladder, large and small intestines, mesenterium, brain, skin, muscle, tail and heart) were removed, briefly washed in physiological saline to remove blood, dried, weighed and counted for radioactivity using an automated NaI(Tl) gamma counter (CobraII Series). In case of tumor-bearing mice, also the left thigh muscle (reference tissue) and the tumor were dissected and treated as mentioned above. Blood was weighed and counted like the organs. The injected activity was calculated by weighing the syringes before and after injection and by the use of a dilution series of the injected tracer solution, which is also weighed and counted for radioactivity using the same CobraII gamma counter. The concentration of radioactivity in the organs was expressed as percentage of the injected dose per gram of tissue (%ID/g). Excretion was recovered and counted for radioactivity and expressed as %ID [7, 9] . Results for tumor uptake were expressed as a ratio %ID/g tumor vs. left thigh muscle as a reference organ.
In vivo imaging
Dynamic gamma camera imaging was performed in NMRI mice using a Toshiba GCA-9300 A/hg SPECT camera in the planar mode equipped with a high-resolution parallel-hole collimator. All images were acquired into 128x128 matrices (FOV: 23.5x12.46 cm) and with a photopeak window set at 15% around 159 keV. At the same time a syringe with a known amount of radioactivity was scanned to allow the semiquantification of the results of the ROI analysis. The animals were anesthetized intraperitoneally with 75 µl (1.5 mg) of a pentobarbital solution (Nembutal, 20 mg/ml, Ceva Santé Animale, Belgium) before starting the imaging experiments. After sedation, 3.7 MBq of [ 123 I]-VEGF 165 was injected via the lateral tail vein. Eighty images of 1 min each were taken. ROIs were drawn using a MRI maximum intensity projection [10] . The stability is expressed as the percentage of intact native labeled peptide (n =3, standard deviations were < 1%).
In order to exclude that increased vascularization is the cause of the tumor to muscle ratio of 6.12 (±2.11), a 99m
Tc-HSA (human serum albumin) planar scintigraphy scan was performed to look at blood flow. Animals (n=5) were sedated as described above and injected with 3.7 MBq of 99m Tc-HSA. One static image was taken from 5 to 10 min p.i. Also, a displacement study was performed using 80 µg of VEGF 165 , co-injected with the tracer. Six animals bearing an A2058 tumor were scanned with [ 123 I]-VEGF 165 by planar scintigraphy at 2 h p.i. as described in vivo imaging to obtain a "baseline" uptake. Before taking a second scan, three of the animals were treated with vehicle (PBS) and three were injected intravenously with 80 µg of VEGF 165 . In order to give more evidence for the specific targeting of the VEGFR, one more experiment was performed. Another cell line, CAPAN-II, which is VEGFR-negative, was inoculated in 5 athymic mice. The uptake of the tracer was measured by dissection as described, 2 h p.i.
Results and discussion
Synthesis of [ 123 I]-VEGF I65 and [ 125 I]-VEGF I65
The overall radiochemical yield using freshly prepared Iodogen vials is 37% 165 with PBS/BSA on PD-10 gives rise to a total eluted fraction of 80%. Nonspecific adsorption on the PD-10 column cannot be decreased using increasing amounts of BSA. Radiochemical purity of the 123 I tracer recovered at end of synthesis was >95%. Stability of the 123 I tracer was >96% for a 4-h incubation period in PBS or DMEM cell growth medium (Table 1 The internalization assay showed uptake of activity in A2058 cells (Fig. 3) . The internalized fraction was maximal at 5 h. Afterwards, the curve shows a decrease. The [
125 I]-VEGF 165 binds to its receptor and is internalized by ligand-induced endocytosis of the VEGF-VEGFR complex. Afterwards, the vesicle containing the peptide is merged with a lysosome and the tracer is metabolized, resulting in rapid excretion of free 123 I -and [
123 I]-iodotyrosine. Moreover, these results indicate that the ligand-receptor interaction has remained intact after iodination of the VEGF 165 . The possible drawback of the internalization is the metabolization of the tracer and the increased background caused by the secreted products.
Biodistribution of [
I]-VEGF 165 and in vivo imaging
Biodistribution of [ 123 I]-VEGF 165 in NMRI mice showed radioactivity uptake in kidneys (30.1 ± 11.2% ID at 1.5 min), liver (14.6±4.9% ID at 1.5 min) and stomach (13.2±3.5% ID at 3 h). A small uptake was seen in the small and large bowel (Figs. 4A and 5 ). Low background activity was observed in lungs, heart, body and head (containing the thyroid, which was not dissected separately). When compared to other iodinated peptides, such as [
123 I]-annexin V [7] or [ 123 I]-hEGF [11] , the rather low dehalogenation profile, as observed in the stomach, is remarkable. Although stomach uptake is still significantly high, it is up to 4 times as low as compared to the other abovementioned radioiodinated peptides. The latter is also confirmed by ROI analysis on both stomach and thyroid on the planar gamma images. Bladder content activity, due to free radioiodine and [
123 I]-iodotyrosine excretion through the kidneys to the bladder, is found to be high. Background levels in the lungs and intestines are strikingly low, as shown by both biodistribution and planar gamma camera images. These results would make it possible to image tumors, overexpressing the VEGFR-1 or -2 receptors, located in these areas.
Biodistribution in A2058 tumor-bearing athymic mice (Fig. 4B) resulted in a ratio of the %ID/g of the tumor vs. thigh of 0.40±0.14, 6.12±2.11, 1.16±0.30 and 0.48±0.12 at 1, 2, 4 and 6 h p.i., respectively. Other organs did not differ significantly from the results obtained from NMRI mice. The 99m Tc-HSA study shows that the uptake of [
123 I]-VEGF 165 in the tumor is not due to increased tumor perfusion: it showed a tumor to muscle ratio of 1.17 (±0.09).
Baseline uptake at 2 h p.i. in A2058-bearing mice resulted in a tumor vs. thigh ratio of 6.01 ±1.95. Vehicle treatment showed no significant difference (ratio= 6.26±1.50; P>>.05). However, co-injection of 80 µg of VEGF 165 resulted in a significant decrease of the A2058 tumor uptake (ratio = 1.30±0.34; P<.05). These results, added with the in vitro displacement study, suggest the specific uptake of the tracer in the tumor. Ratio tumor vs. thigh of the CAPAN-II-bearing mice was 1.11±0.23.
Because of the absence of labeled catabolites of the tracer, only the native [
123 I]-VEGF 165 and free radioiodine are present in plasma. Of these, only the labeled VEGF 165 can bind to the VEGFR, confirmed by the in vitro displacement experiment. 
Conclusion
Given the preserved receptor-ligand interactions and the high receptor affinity, its low in vivo background activity due to relatively low dehalogenation and good tumor uptake, we conclude that [
123 I]-VEGF 165 is a potent tool to perform VEGF receptor scintigraphy in vivo. 
